Atractylenolide I Attenuates Glucocorticoid-Induced Osteoporosis via Inhibiting NF-κB Signaling Pathway
Calcified Tissue International · 2025
DOI: 10.1007/s00223-025-01358-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Calcified Tissue International, 2025. Verfasst von Yamei Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China. Hauptthemen laut MEDLINE: Osteoporosis, Signal Transduction, Sesquiterpenes, NF-kappa B. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Long-term treatment with glucocorticoids significantly impacts bone health, with glucocorticoid-induced osteoporosis (GIOP) being the most prevalent consequence. Previous studies have established that Atractylenolide I (Atr I) possesses anti-inflammatory, antioxidant and anti-tumor properties, however, its specific effects on osteoclastogenesis and GIOP are still unclear. In this study, our in vitro results revealed that Atr I inhibited RANKL-stimulated osteoclast differentiation in a dose-dependent manner, disrupted the structure of the F-actin belt in mature osteoclasts, blocked RANKL-induced ROS production, and suppressed the expression of osteoclast-associated genes. Mechanistically, the findings indicated that Atr I inhibited the RANKL-induced activation of the NF-κB signaling pathway. In vivo, the micro-CT, bone histomorphometric analysis and histological data demonstrated that Dex administration led to significant bone loss, accompanied by a considerable increase in the number of osteoclasts on the bone surface. Conversely, treatment with Atr I effectively prevented these Dex-induced alterations. Taken together, this study suggests that Atr I may hold potential as a therapeutic agent for the treatment of GIOP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
- School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
- Laboratory of Orthopaedics and Traumatology, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
- The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
- Laboratory of Orthopaedics and Traumatology, Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China. xull-2016@gzucm.edu.cn.
- The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China. xull-2016@gzucm.edu.cn.
ORCID-Profile: Liangliang Xu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, Y., Deng, X., Chen, C., Fu, B., Wang, M., Li, J., Xu, L., & Wang, B. (2025). Atractylenolide I Attenuates Glucocorticoid-Induced Osteoporosis via Inhibiting NF-κB Signaling Pathway. Calcified Tissue International. https://doi.org/10.1007/s00223-025-01358-w
Vancouver
Liu Y, Deng X, Chen C, Fu B, Wang M, Li J, et al. Atractylenolide I Attenuates Glucocorticoid-Induced Osteoporosis via Inhibiting NF-κB Signaling Pathway. Calcified Tissue International. 2025. doi:10.1007/s00223-025-01358-w
BibTeX
@article{Liu2025,
author = {Liu, Yamei and Deng, Xiaoqi and Chen, Chen and Fu, Binlan and Wang, Min and Li, Jinglan and Xu, Liangliang and Wang, Bin},
title = {Atractylenolide I Attenuates Glucocorticoid-Induced Osteoporosis via Inhibiting NF-κB Signaling Pathway},
journal = {Calcified Tissue International},
year = {2025},
doi = {10.1007/s00223-025-01358-w}
}
EUVIMED